This Expert Review features internationally-renowned thought leaders discussing the latest data regarding the use of PARP inhibitors in ovarian cancer, including efficacy data, safety issues, and future directions.
Dec 21, 2017
Dec 21, 2018
Susana Banerjee, MBBS, MA, MRCP, PhDRoyal Marsden Hospital
Institute of Cancer Research
London, United Kingdom
Antonio González-Martín, MDClínica Universidad de Navarra
Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute, University College London
London, United Kingdom
Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix
Creighton University School of Medicine at St. Joseph's Hospital
Phoenix, Arizona, United States
- Module 1 – Incorporating PARP Inhibitors Into the Treatment of Ovarian Cancer
- Module 2 – Safety Issues With PARP Inhibitors
- Module 3 – What’s on the Horizon for the Use of PARP Inhibitors in the Treatment of Ovarian Cancer?
This educational activity is supported by grants from AstraZeneca, Clovis, and Tesaro.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.